WIRB-Copernicus launches product aimed at institutions and research sites

Businessman video-chats with doctor on laptop
WIRB-Copernicus Group launched a new product aimed at upping the efficiency and profitability of clinical research operators at institutions and independent research sites. (Getty/AndreyPopov)

Clinical trial specialist WIRB-Copernicus Group launched a new product aimed at upping the efficiency and profitability of clinical research operators at institutions and independent research sites.

Dubbed SiteReady, the product is an end-to-end solution designed to make research more efficient and easier to manage by reducing the administrative burden of regulatory compliance, streamlining contract and budget negotiations, speeding up study start-up and builds patient enrollment in clinical trials.

“The research ecosystem is changing rapidly; protocols are increasingly complex, research teams are stretched thin, and patients are more informed than ever,” Donald Deieso, chair and CEO of WCG, said in a statement. “Biopharmaceutical companies are seeking investigators who can perform clinical studies at the highest level of efficiency and integrity.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Conversely, leading investigative sites desire opportunities to participate in the exciting advances being developed by the industry. To succeed in this highly competitive landscape, investigators and site teams must continually position themselves for growth.”

Earlier this year WCG upped its presence in the clinical trial management solutions business with the addition of CTMS specialist Velos eResearch. That deal fell six months after WCG snapped up KMR Group and Metrics Consortium in an acquisition, bolstering is market insights and intelligence division.

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.